Walleye Capital
REGN icon

Walleye Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Walleye Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$927K Sell
1,200
-2,600
-68% -$1.99M ﹤0.01% 2140
2025
Q4 		$2.93M Buy
3,800
+100
+3% +$67.9K 0.01% 1552
2025
Q3 		$2.08M Sell
3,700
-4,700
-56% -$2.66M 0.01% 1552
2025
Q2 		$4.41M Buy
8,400
+2,300
+38% +$1.28M 0.02% 945
2025
Q1 		$3.87M Sell
6,100
-2,100
-26% -$1.44M 0.02% 958
2024
Q4 		$5.84M Buy
8,200
+100
+1% +$83.9K 0.01% 973
2024
Q3 		$8.52M Hold
8,100
– – 0.02% 797
2024
Q2 		$8.51M Sell
8,100
-6,000
-43% -$5.82M 0.02% 879
2024
Q1 		$13.6M Buy
14,100
+10,800
+327% +$10.3M 0.02% 636
2023
Q4 		$2.9M Sell
3,300
-6,500
-66% -$5.35M 0.01% 1502
2023
Q3 		$8.07M Buy
9,800
+3,300
+51% +$2.59M 0.02% 696
2023
Q2 		$4.67M Buy
6,500
+100
+2% +$77.1K 0.02% 770
2023
Q1 		$5.26M Buy
6,400
+6,100
+2,033% +$4.6M 0.08% 309
2022
Q4 		$216K Hold
300
– – ﹤0.01% 1985
2022
Q3 		$207K Buy
+300
New +$189K ﹤0.01% 2090
2020
Q1 		– Sell
-4,500
Closed -$1.69M – 1520
2019
Q4 		$1.69M Sell
4,500
-30,900
-87% -$10.4M 0.11% 253
2019
Q3 		$9.82M Buy
35,400
+24,400
+222% +$7.22M 0.58% 14
2019
Q2 		$3.44M Buy
11,000
+4,500
+69% +$1.5M 0.38% 28
2019
Q1 		$2.67M Buy
+6,500
New +$2.68M 0.44% 7

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Walleye Capital's REGN Position: Q1 2026 in Review

Walleye Capital reduced its Regeneron Pharmaceuticals (REGN) stake by 89% in Q1 2026, selling an estimated $24.1M and leaving 4,022 shares worth $3.11M. The position accounts for 0.01% of the portfolio, ranked #1124.

Walleye Capital first reported a position in REGN in Q1 2019 and has held it in 19 quarters since. The position peaked at $49.2M in Q3 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Walleye Capital held 4,022 shares of Regeneron Pharmaceuticals worth $3.11M as of Q1 2026.
  • Walleye Capital sold 31,478 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $24.1M.
  • Regeneron Pharmaceuticals made up 0.01% of Walleye Capital's portfolio in Q1 2026, its #1124 holding.
  • Walleye Capital first reported a position in Regeneron Pharmaceuticals in Q1 2019 and has held it in 19 quarters since.
  • Walleye Capital's Regeneron Pharmaceuticals position peaked at $49.2M in Q3 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.